CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 108 enrolled
Drug / intervention
Semaglutide Injectable Product +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04019197
NCT04019197Phase 2Active
CompareCT.gov

Effects of GLP-l Receptor Agonists on Cardiometabolic Alterations in HIV-associated Lipohypertrophy

Case Western Reserve University·interventional·Posted Jul 15, 2019·Updated May 4, 2026

In Brief

A Phase 2 clinical trial evaluating Semaglutide Injectable Product and Placebo for HIV/AIDS and 2 related conditions. Active but no longer recruiting, targeting 108 participants across 2 sites.

Detailed Summary

This is a randomized, double-blinded, placebo-controlled trial designed to assess the effect of the GLP-1 receptor agonist, semaglutide, on visceral and ectopic fat, insulin resistance, inflammation markers, and the downstream effect of cardiovascular risk in people with HIV. The primary endpoints will be visceral and ectopic fat changes over the study period. The secondary endpoints will include changes in markers of inflammation, immune activation, gut integrity, and cardiovascular disease risk assessment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV/AIDS, Lipohypertrophy, Obesity
CountriesUnited States
CollaboratorsMedical University of South Carolina, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 2Active
2020202120222023202420252026
First PostedJul 15, 2019
Enrollment StartMay 16, 2019
Primary CompletionApr 30, 2024
Study CompletionSep 1, 2026
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 7.0 years ago

Interventions

Semaglutide Injectable Productdrug

semaglutide subcutaneous injection

Placebodrug

placebo injection